0001750149-24-000002.txt : 20240604 0001750149-24-000002.hdr.sgml : 20240604 20240604161131 ACCESSION NUMBER: 0001750149-24-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240604 DATE AS OF CHANGE: 20240604 EFFECTIVENESS DATE: 20240604 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263407249 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-515107 FILM NUMBER: 241018108 BUSINESS ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 678-392-3419 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 D 1 primary_doc.xml X0708 D LIVE 0001750149 Inhibikase Therapeutics, Inc. 3350 RIVERWOOD PARKWAY SE, SUITE 1900 Atlanta GA GEORGIA 30339 678-392-3419 DELAWARE Inhibikase Therapeutics, LLC None Corporation true Milton H. Werner c/o Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta GA GEORGIA 30339 Executive Officer Director Chief Executive Officer, President and Director Garth Lees-Rolfe c/o Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta GA GEORGIA 30339 Executive Officer Chief Financial Officer Dennis Berman c/o Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta GA GEORGIA 30339 Director Roy Freeman c/o Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta GA GEORGIA 30339 Director Paul Grint c/o Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta GA GEORGIA 30339 Director Gisele Dion c/o Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta GA GEORGIA 30339 Director Pharmaceuticals Decline to Disclose 06b false 2024-05-20 false true true true false 0 Maxim Group LLC 120708 None None 300 Park Avenue 16th Floor New York NY NEW YORK 10022 All States false 7999999 0 7999999 Reflects proceeds from the sale of 4,761,904 warrants, each to purchase 1 share of common stock, with an exercise price per share of $1.68, if all such warrants were exercised. false 1 339994 0 Amount paid in connection with this offering of warrants and a concurrent offering of common stock, consisting of a $182,625.53 placement agent fee and expenses of $80,000. 0 false Inhibikase Therapeutics, Inc. /s/ Garth Lees-Rolfe Garth Lees-Rolfe Chief Financial Officer 2024-06-04